Physician profile
Leonard Feiner
NPI 1841208014
$72,282.74
in general payments reported to CMS, 2019-2025
13 companies · $383 in 2025
The $383 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $19K · 2021: $14K · 2022: $11K · 2023: $9,757 · 2024: $5,134 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $920 · Food and Beverage: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,524.97 |
| Travel and Lodging | $919.72 |
| Food and Beverage | $829.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $44,706.28 | 2020-2025 | Eylea Hd, Eylea |
| Genentech, INC. | $13,545.15 | 2019-2021 | |
| Genentech USA, INC. | $7,084.29 | 2019-2024 | Vabysmo |
| Otsuka America Pharmaceutical, INC. | $5,500.00 | 2019 | |
| Becton, Dickinson and Company | $900.00 | 2022 | |
| Apellis Pharmaceuticals, INC. | $136.08 | 2022-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $125.35 | 2025 | Envista Aspire Iol |
| Novo Nordisk INC | $124.99 | 2025 | Ozempic |
| Abbvie INC. | $75.94 | 2023-2025 | |
| Sandoz INC. | $35.50 | 2024 | Cimerli |
| Astellas Pharma US INC | $20.00 | 2025 | Izervay |
| Alimera Sciences, INC. | $15.00 | 2019 | |
| Ocular Therapeutix, INC. | $14.16 | 2024 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Feiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.